Myeloproliferative Neoplasms (MPN) Study

What we are studying

We are attempting to better understand the causes of myeloproliferative neoplasms (MPN) and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue learning more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is our belief that further basic knowledge about these cancer cells, as well as the effects of treatment, will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. We are hoping to determine if a number of laboratory tests (biomarkers) will allow us to predict if future patients will respond to the treatment you are receiving.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Patients diagnosed with the following myeloproliferative neoplasms including:
    • Polycythemia vera (PV)
    • Primary myelofibrosis (PMF)
    • And essential thrombocythemia (ET)

What is involved

  • Blood and bone marrow samples at the following times: at diagnosis or before starting treatment; time points during treatment; if/when the disease responds to treatment
  • If/When the disease comes back
  • Toenail clippings obtained at diagnosis or before starting treatment

Compensation

None

Contact Information

Study Coordinator
Thomas Freeman
Email
thfreema@wakehealth.edu
Phone
Not Listed

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.